Cargando…

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma

Detalles Bibliográficos
Autores principales:	Ruffini, Federica, Graziani, Grazia, Levati, Lauretta, Tentori, Lucio, Caporali, Simona, D’Atri, Stefania, Lacal, Pedro M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315286/ http://dx.doi.org/10.1186/1479-5876-13-S1-P6

Ejemplares similares

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017)

Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
por: Caporali, Simona, et al.
Publicado: (2015)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
por: Caporali, Simona, et al.
Publicado: (2017)

Neuropilin-1 as Therapeutic Target for Malignant Melanoma
por: Graziani, Grazia, et al.
Publicado: (2015)

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
por: Caporali, Simona, et al.
Publicado: (2019)

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
por: Levati, Lauretta, et al.
Publicado: (2022)

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding
por: Graziani, Grazia, et al.
Publicado: (2016)

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
por: Caporali, Simona, et al.
Publicado: (2012)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

microRNAs and next generation sequencing for the prognosis of the metastatic melanoma
por: Pinto, Rosamaria, et al.
Publicado: (2015)

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
por: Atzori, Maria Grazia, et al.
Publicado: (2017)

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
por: Ceci, Claudia, et al.
Publicado: (2020)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor
por: Atzori, Maria Grazia, et al.
Publicado: (2022)

Melanoma and Vitiligo: In Good Company
por: Failla, Cristina Maria, et al.
Publicado: (2019)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Metabolic mechanisms regulating distinct steps of the melanoma metastatic cascade
por: Piskounova, Elena, et al.
Publicado: (2014)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Neuropilin‐1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1
por: Colotti, Gianni, et al.
Publicado: (2021)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

Bevacizumab resistance in breast cancer: are neuropilins the key?
por: Staton, CA, et al.
Publicado: (2008)

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma
por: Sarnaik, Amod, et al.
Publicado: (2015)

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
por: Ceci, Claudia, et al.
Publicado: (2018)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma
por: Audrito, Valentina, et al.
Publicado: (2018)

Expression of neuropilin-1 on in vivo induced regulatory T cells
por: Nirschl, Christopher J, et al.
Publicado: (2013)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Diversity of mutated antigen recognition by tumor infiltrating lymphocytes from patients with metastatic melanoma
por: Crystal, Jessica S, et al.
Publicado: (2015)

6. Treatment resistant ulcerating dermatomyositis in metastatic melanoma treated with checkpoint inhibitor therapy
por: Parker, Lucy, et al.
Publicado: (2019)

Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients
por: Sandru, Angela, et al.
Publicado: (2015)

Exome sequencing in primary melanoma identifies novel drivers of melanoma progression
por: Montagnani, Valentina, et al.
Publicado: (2015)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma
por: LU, JING, et al.
Publicado: (2015)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l6l9qu3mqpf4uc48ctibbq4p70